Jazz Pharmaceuticals Spotlights Epidiolex® Benefits For Treatment-Resistant Epilepsy At AES 2024

Jazz Pharmaceuticals plc announced the presentation of nine new posters showcasing Epidiolex® (cannabidiol) at the American Epilepsy Society (AES) 2024 Annual Meeting in Los Angeles, California, from December 6-10. The featured research includes updated real-world data from the BECOME-TSC survey, highlighting how Epidiolex impacts both seizures and non-seizure challenges in patients with epilepsy and tuberous sclerosis complex (TSC). 

Another key study, the BECOME-LTC survey, reflects insights from nurses in long-term care settings, reporting improved seizure control and other benefits in patients using Epidiolex. Additionally, new findings from the EpiCom trial revealed that Epidiolex treatment led to noticeable improvements in behavior-related symptoms for patients with TSC-associated neuropsychiatric disorders (TAND). These presentations reinforce Epidiolex’s growing evidence base and its role in improving outcomes for individuals with complex epilepsy.

Sarah Akerman, MD, Head of Neuroscience Global Medical and Scientific Affairs Of Jazz Pharmaceuticals, said in a statement, "Our real-world data presentations at AES 2024, including novel findings from the BECOME-LTC, BECOME-TSC and EpiCom studies, demonstrate the meaningful impact of Epidiolex in the treatment of patients with rare epilepsies. These findings increase our understanding of Epidiolex's benefits beyond seizure control, addressing unmet needs across a range of epilepsy syndromes for people living with rare epilepsies and demonstrating reproducibility and consistency of effect across different populations.”